The global digital therapeutics market is projected to reach USD 13.1 billion by 2026 from USD 3.4 billion in 2021, at a CAGR of 31.4% during the forecast period
To know about the assumptions considered for the study @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=51646724
Growth in this market is primarily driven by the increasing incidence of preventable chronic diseases, the need to control healthcare costs, rising focus on preventive healthcare, and rising investments in digital therapeutics.
Global Digital Therapeutics (DTx) Market Scope:
Metrics | Details |
Study Period | 2022–2026 |
Market Size in 2026 | USD 13.1 Billion |
Segment Covered | Sales Channel, Application, and Region |
by Sales Channel Covered | B2C, Patient, Caregiver, B2B, Providers, Payer, Employer, Pharma |
By Application Covered | Prediabetes, Nutrition, Care, Diabetes, CVD, CNS, CRD, MSD, GI, Substance Abuse, Rehabilitation |
Regions Covered | North America, Europe, Asia Pacific, Middle East and Africa, and South America |
Key Players Profiled | Noom (US), Livongo Health (US), Omada Health (US), WellDoc (US), Pear Therapeutics (US), Proteus Digital Health (US), Propeller Health (US), Akili Interactive Labs (US), Better Therapeutics (US), Happify (US), Kaia Health (Germany), Mango Health (US), Click Therapeutics (US) |
Noom (US)
Noom (US) is one of the leading providers of the digital therapeutics market. The company provides best-in-class solutions for weight management, hypertension prevention, hypertension management, diabetes prevention, diabetes management, and comorbidities of hypertension and diabetes.
Omada (US)
Omada is one of the leading players in the digital therapeutics market. The company is engaged in designing and developing innovative digital therapeutic programs for preventable chronic diseases, including type 2 diabetes and heart disease. The company sells its products to major organizations, integrated delivery networks, and health plans.
Livongo Health (US)
Livongo Health (US) is one of the prominent players in the digital therapeutics market. The company focuses mainly on digital solutions for the management of chronic diseases. The company’s diabetes management solution has helped in reducing medical spending.
Click Here to Access a Free Sample Report of the Global Digital Therapeutics (DTx) Market @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=51646724
Recent Developments:
- In April 2021, Welldoc(US) partnered with Dexacom (US). This partnership helped provide BlueStar with Dexcom G6 CGM as a single platform to people with Type 2 diabetes for improved health.
- In March 2021, Pear Therapeutics (US) partnered with Sprectrum Health Systems (US). Tufts Health Plan and Spectrum Health Systems announced a collaboration with Pear Therapeutics to test FDA-approved digital therapeutics to help people with substance use disorders and improve their recovery journeys by delivering solutions for improved treatment access and care innovation journeys by delivering solutions for improved treatment access and care innovation
Our Free Sample Report Consists of the following:
- Introduction, Overview, and in-depth industry analysis are all included in the 2022 updated report.
- The COVID-19 Pandemic Outbreak Impact Analysis is included in the package
- About 220+ Pages Research Report (Including Recent Research)
- Provide detailed chapter-by-chapter guidance on Request
- Updated Regional Analysis with Graphical Representation of Size, Share, and Trends for the Year 2022
- Includes Tables and figures have been updated
- The most recent version of the report includes the Top Market Players, their Business Strategies, Sales Volume, and Revenue Analysis
Directly Purchase a copy of the report [204] @ https://www.marketsandmarkets.com/Purchase/purchase_reportNew.asp?id=51646724
